



Docket No.: 63472(50533)
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Application of:
Signe M. Christensen et al.

Application No.: 10/535,472

Confirmation No.: 4416

Filed: December 19, 2005

Art Unit: N/A

For: AMINO-LNA, THIO-LNA AND ALPHA-L-
OXY-LN

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

Applicant has not submitted copies of each cited U.S. patent and U.S. patent application as required by 37 CFR 1.98(a)(2)(i), amended October 2004, as the U.S. Patent and Trademark Office has waived this requirement for all U.S. patent applications. Applicant submits herewith copies of foreign and non-patents in accordance with 37 CFR 1.98(a)(2).

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1105, under Order No. 63472(50533).

Dated: April 21, 2006

Respectfully submitted,



Stephana E. Patton

Registration No.: 50,373


EDWARDS ANGELL PALMER & DODGE
LLP

P.O. Box 55874

Boston, Massachusetts 02205

(617) 439-4444

Attorneys/Agents For Applicant



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/535,472-Conf. #4416
				Filing Date	December 19, 2005
				First Named Inventor	Signe M. Christensen
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	63472(50533)
Sheet	1	of	3		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	BA	WO-WO 99/14226	03-25-1999			
	BB	WO-WO 98/39352	09-11-1998			
	BC	WO-WO 01-48190 A2	07-05-2001			
	BD	WO-WO 00/66604 A2	11-09-2000			
	BE	WO-WO 01/25478 A1	04-12-2001			
	BF	WO-WO 01/25248 A2	04-12-2001			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Neilsen et al., "Synthesis of 2'-0,3'-C linked bicyclic nucleosides and bicyclic oligonucleotides" J. Chem. Soc., Perkin Trans. 1, pp. 3423-3433 (1997).	
	CB	Nielsen et al., "A novel class of conformationally restricted oligonucleotide analogues: synthesis of 2', 3' -bridged monomers and RNA-selective hybridisation", Chem. Commun., 9:825-826 (1997).	
	CC	Christensen, et al., "A novel class of oligonucleotides analogues containing ...", J. Am chem Society, 120:5458-5463 (1998)	
	CD	Koshkin et al., "Synthesis of Novel 2',3'-Linked Bicyclic Thymine Ribonucleotides", J. Org. Chem., 63(8):2778-2781 (1998)	
	CE	Koshkin et al, "The First Analogues of LNA (Locked Nucleic Acids): Phosphorothioate-LNA 2'-THIO-LNA", J. Am Chem. Soc., 120(50): 13252-13253	
	CF	Kumar et al., "Design and characterization of decoy oligonucleotides containing locked nucleic acids" Bioorg & Med. Chem. Lett., 8:2219-2222 (1998)	
	CG	Braasch et al., "Implications of High-Affinity Hybridization by Locked Nucleic Acid Oligomers for Inhibition of Human Telomerase", Biochemistry, 41(14): 4503-4510 (2002)	
	CH	Crinelli et al. "Design and characterization of decoy oligonucleotides containing locked nucleic acids", Nucl. Acid Res., 30(11):2435-2443 (2002)	
	CI	Elayadi et al., "Implications of High-Affinity Hybridization by Locked Nucleic Acid Oligomers for	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/535,472-Conf. #4416
				Filing Date	December 19, 2005
				First Named Inventor	Signe M. Christensen
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	3	Attorney Docket Number	63472(50533)

		Inhibition of Human Telomerase" Biochemistry, 41:9973-9981 (2002)	
	CJ	Jacobsen et al., "LNA-enhanced detection of single nucleotide polymorphisms in the apolipoprotein E", Nucl. Acid Res., 30(19), in press (2002)	
	CK	Kurreck et al., "Design of antisense oligonucleotides stabilized by locked nucleic acids" Nucl. Acid Res. 30(9), 1911-1918 (2002)	
	CL	Obika et al., "2'-O,4'-C-Methylened Bridged..." Bioorg & Med. Chem., 9:1001-1011 (2001)	
	CM	Braasch et al., "Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA", Chem. & Bio., 55:1-7 (2000)	
	CN	Wahlestedt et al., "Potent and nontoxic antisense oligonucleotides containing locked nucleic acids", PNAS, 97 (10): 5633-5638 (2000)	
	CO	Freier et al., "The ups and downs of nucleic acid duplex stability: structure-stability studies on chemically-modified DNA:RNA duplexes" Nucl. Acid Res., 25(22):4429-4443 (1997)	
	CP	Cook, "Making drugs out of oligonucleotides: a brief review and perspective" Nucleosides & Nucleotides, 18 (6&7), 1141-62 (1999).	
	CQ	Singh, "Synthesis of Novel Bicyclo...", J. Org. Chem., 63:6078-6079 (1998)	
	CR	Singh et al, "The Adenine Derivative..." J. Org. chem. 63:10035-10039 (1998)	
	CS	Rajwanshi et al., "High-affinity nucleic acid recognition using 'LNA' ..." J Chem. Commun, pp. 2073-2074 (1999)	
	CT	Hakansson et al., "The Adenine Derivative of x-L-LNA (a-L-ribo Configured Locked Nucleic Acid): Synthesis and High-Affinity" Bioorg Med. Chem Lett, 11:935-938 (2001)	
	CU	Rajwanshi et al., "LNA stereoisomers: xylo-LNA..." Chem. Commun., pp. 1395-1396 (1999)	
	CV	Wengel et al., "LNA (Locked Nucleic Acid) And the Diastereoisomeric...", Nucleotides & Nucleic Acids, 20(4-7):389-396 (2001)	
	CW	Rajwanshi et al., "The Eight Stereoisomers of LNA (Locked Nucleic Acid): A Remarkable Family of Strong RNA Binding Molecules" Angew Chem. Int. Ed., 39(9):1656-1659 (2000)	
	CX	Petersen et al., "a-L-LNA...", J. Am. Chem. Soc., 123:7431-7432 (2001)	
	CY	Sorensen et al., "a-L-ribo-Configured Locked Nucleic Acid (a-L-LNA): Synthesis and Properties", J. Am Chem. Soc., 124(10):2164-2176 (2002)	
	CZ	Vester et al., "LNazymes: Incorporation of LNA-Type Monomers into DNazymes Markedly Increases RNA Cleavage", J. Am Chem. Soc., 124(46):13682-13683	
	CA1	Arzumanov et al, "Inhibition of HIV-1 Tat-Dependent Trans Activation by Steric Block Chimeric 2'-O Methyl/LNA Oligoribonucleotides", Biochemistry 40:14645-1465 (2001)	
	CB1	Zamecnik et al, "Inhibition of Rous sarcoma virus replication and cell transformation", PNAS, 75(1):280-284 (1978)	
	CC1	Bennett et al., "Antisense oligonucleotides as a tool for gene functionalization and target validation" Biochim. Biophys. Acta, 1489:19-30 (1999)	
	CD1	Crooke, "Antisense Therapeutics", Biotechnol. Genet. Eng. Rev., 15:121-57 (1998)	
	CE1	Wengel, J., "LNA (Locked Nucleic Acid)", In Antisense Drug Technology: Principles, pp. 339-355 (2001)	
	CF1	Simeonov et al., "Single nucleotide polymorphism genotyping using short, fluorescently labeled locked..." Nucleic Acids Research, 30(17), in press (2002)	
	CG1	Childs et al., "Oligonucleotide directed misfolding of RNA inhibits Candida albicans group I intron splicing", PNAS, 99(17):11091-11096 (2002)	
	CH1	L. KIENICKE et al., "alpha-L-RNA (alpha-L-ribo Configured 'RNA): Synthesis and RNA-Selective Hybridization of alpha-L-RNA/alpha-L-LNA Chimera." Bioorganic & Medicinal Chemistry Letters, Vol. 12, 4, 2002 pages 593-596	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/535,472-Conf. #4416
				Filing Date	December 19, 2005
				First Named Inventor	Signe M. Christensen
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	3	of	3	Attorney Docket Number	63472(50533)

CI1	M. FRIEDEN et al., "Expanding the design horizon of antisense oligonucleotides with alpha-L-LNA," Nucleic Acids Research, Vol. 31, No. 21, 2003, pp. 6365-6372.
-----	---

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



04-24-06

Jpr

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/535,472-Conf. #4416
	Filing Date	December 19, 2005
	First Named Inventor	Signe M. Christensen
	Art Unit	N/A
	Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	Attorney Docket Number	63472(50533)

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Form PTO/SB/08a/b (41 referemces) (3 pages) Copies of 41 References Return Receipt Postcard
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	EDWARDS ANGELL PALMER & DODGE LLP		
Signature			
Printed name	Stephana E. Patton		
Date	April 21, 2006	Reg. No.	50,373



Application No. (if known): 10/535,472


Attorney Docket No.: 63472(50533)

Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. EV 755070274 US in an envelope addressed to:

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on April 21, 2006
Date



Signature

Safiya Jarvis

Typed or printed name of person signing Certificate

Registration Number, if applicable

Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Transmittal (1 page)
Information Disclosure Statement (2 pages)
IDS (Citation) by Applicant (41 References) (3 pages)
Copies of 41 References
Return Receipt Postcard